Study Identifies Key Mechanisms of a Common Complication of Crohn’s Disease
Lenvatinib Plus Tislelizumab Offers Antitumor Activity for First-line Treatment of uHCC
FDA Approves High-Concentration Cyltezo for Treatment of Chronic Inflammatory Diseases